Eton Launches IMPAVIDO Capsules in US
News related to:Eton Pharmaceuticals · 3 min read
DEER PARK, Ill., Sept. 28, 2026 /CourierPR/ -- Eton Pharmaceuticals, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the launch of IMPAVIDO® (miltefosine) capsules in the United States. The company now holds exclusive commercialization rights for IMPAVIDO, a drug that is indicated for the treatment of visceral leishmaniasis, cutaneous leishmaniasis, and mucosal leishmaniasis due to Leishmania species. Eton has integrated full Eton Cares® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs, into the IMPAVIDO commercial infrastructure.
Centralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination. Clinicians seeking to prescribe IMPAVIDO can e-prescribe by selecting Anovo #5 (Memphis) or fax a patient referral form to 855-813-2039. Patients with questions regarding their prescription or healthcare providers can call Anovo at the dedicated IMPAVIDO line 877-469-4078. Hospital pharmacies seeking IMPAVIDO for inpatient use may contact Anovo Specialty Pharmacy to establish access through the hospital network.
For urgent or time-sensitive patient needs, Anovo will coordinate an emergency access pathway with treating clinicians, CDC representatives, and hospital pharmacies. The pathway is designed to evaluate the fastest available source of product and delivery option based on the patient’s need-by time and the treating institution’s location.
Additional product details can be found on the product website, www.impavidous.com. IMPAVIDO is contraindicated in pregnancy because it may cause fetal harm; in patients with Sjögren-Larsson syndrome; and in patients with hypersensitivity to miltefosine or any component of the formulation. IMPAVIDO is indicated for the treatment of visceral leishmaniasis due to Leishmania donovani, cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis, and mucosal leishmaniasis due to Leishmania braziliensis. The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.
Clinicians seeking to prescribe IMPAVIDO can e-prescribe by selecting Anovo #5 (Memphis) or fax a patient referral form to 855-813-2039. Patients with questions regarding their prescription or healthcare providers can call Anovo at the dedicated IMPAVIDO line 877-469-4078. Hospital pharmacies seeking IMPAVIDO for inpatient use may contact Anovo Specialty Pharmacy to establish access through the hospital network. For urgent or time-sensitive patient needs, Anovo will coordinate an emergency access pathway with treating clinicians, CDC representatives, and hospital pharmacies. The pathway is designed to evaluate the fastest available source of product and delivery option based on the patient’s need-by time and the treating institution’s location.
Eton Pharmaceuticals, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the launch of IMPAVIDO® (miltefosine) capsules in the United States. The company now holds exclusive commercialization rights for IMPAVIDO, a drug that is indicated for the treatment of visceral leishmaniasis, cutaneous leishmaniasis, and mucosal leishmaniasis due to Leishmania species. Eton has integrated full Eton Cares® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs, into the IMPAVIDO commercial infrastructure.
Centralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination. Clinicians seeking to prescribe IMPAVIDO can e-prescribe by selecting Anovo #5 (Memphis) or fax a patient referral form to 855-813-2039. Patients with questions regarding their prescription or healthcare providers can call Anovo at the dedicated IMPAVIDO line 877-469-4078. Hospital pharmacies seeking IMPAVIDO for inpatient use may contact Anovo Specialty Pharmacy to establish access through the hospital network.
For urgent or time-sensitive patient needs, Anovo will coordinate an emergency access pathway with treating clinicians, CDC representatives, and hospital pharmacies. The pathway is designed to evaluate the fastest available source of product and delivery option based on the patient’s need-by time and the treating institution’s location.
Additional product details can be found on the product website, www.impavidous.com.